Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition for preventing and controlling alzheimer's disease or apolexis

A technology for Alzheimer's disease and a composition, applied in the field of medicine, can solve the problems of unclear pathogenesis of AD, lack of prevention and treatment, etc., achieve prevention and treatment of Alzheimer's disease and aging, and improve energy metabolism of brain cells , the effect of great theoretical significance

Inactive Publication Date: 2008-12-10
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the exact pathogenesis of AD is still unclear, and effective prevention and treatment measures are lacking.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1 Animal experiment

[0021] 1) preparation of pyrroloquinoline quinone in different dosage forms

[0022] According to conventional methods, pyrroloquinoline quinone tablets, powders, powder injections, rectal suppositories, skin patches (transdermal administration), aqueous injections, sprays, etc. were prepared respectively;

[0023] 2) Clinical application experiments of different dosage forms of pyrroloquinoline quinone,

[0024] Apply different dosage forms of pyrroloquinoline quinone, through different routes of oral (including) administration, intramuscular injection, intraperitoneal injection, intravenous injection, spray administration, rectal administration or transdermal administration, using 0.1 mg-1000 mg per day to prevent or to treat Alzheimer's disease or aging;

[0025] 3) Animal experiment curative effect observation,

[0026] By oral or intraperitoneal injection, Kunming natural aging mice and transgenic Alzheimer's disease model mice w...

Embodiment 2

[0030] 1, conventional method prepares pyrroloquinoline quinone tablet;

[0031] 2. By oral administration, give 6-month-old transgenic AD model mice or 12-month-old wild Kunming mice a daily dose of 0.1 mg-1000 mg pyrroloquinoline quinone for 6 consecutive months;

[0032] 3. Continuously or divided into different periods of administration for up to 6 months, with a daily dosage of 0.1 mg to 1000 mg, wherein pyrroloquinoline quinone plus benfotiamine; or benfotiamine and coenzyme Q10 are used. Among them, the dose of pyrroloquinoline quinone is 0.1 mg to 1000 mg per day, and the daily dose of benfotiamine or coenzyme Q10 is 1 mg to 1000 mg respectively.

[0033] The results showed that the mice in the treatment group had the effect of significantly improving cognitive function and prolonging the average life expectancy of the mice, and the combined application of pyrroloquinoline quinone, benfotiamine and / or coenzyme Q10 had the effect of preventing and treating Alzheimer's d...

Embodiment 3

[0035] 1. Prepare pyrroloquinoline quinone aqueous injection by conventional method;

[0036] 2. Through the intraperitoneal administration route, give 6-month-old transgenic AD model mice or 12-month-old wild Kunming mice a daily dose of 0.1 mg-1000 mg pyrroloquinoline quinone for 6 consecutive months;

[0037] 3. Continuously or divided into different periods of administration for up to 6 months, with a daily dosage of 0.1 mg to 1000 mg, wherein pyrroloquinoline quinone plus benfotiamine; or benfotiamine and coenzyme Q10 are used. Among them, the dose of pyrroloquinoline quinone is 0.1 mg to 1000 mg per day, and the daily dose of benfotiamine or coenzyme Q10 is 1 mg to 1000 mg respectively.

[0038] The results showed that the mice in the treatment group had the effect of significantly improving cognitive function and prolonging the average life expectancy of the mice, and the combined application of pyrroloquinoline quinone, benfotiamine and / or coenzyme Q10 had the effect o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention pertains to the technical field of medicine and relates to a combination of PQQ, benfotiamine and / or coenzyme Q10 medicine and the preparation method and application thereof to the prevention and cure of alzheimer's disease or senescence. Experiments on animals prove that the medicine combination of the present invention has functions of improving wild type mitochondrion and mitochondrion of the Alzheimer's disease aging mouse, has function of cleaning free radical in vivo and antagonizing oxidized injury. Therefore, the cognition function of the mouse can be remarkably improved and the average life expectancy can be prolonged. The combination has the function of preventing and curing the Alzheimer's disease or the senescence and broad clinical application prospect. The combination can be used for preparing medicine for preventing and curing the alzheimer's disease or the senescence.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a pharmaceutical composition for preventing and treating Alzheimer's disease or aging and a preparation method thereof. Background technique [0002] Alzheimer's disease (AD) is a chronic, age-related brain degenerative disease, mainly manifested by impairment of brain cognitive functions such as learning and memory. With the acceleration of population aging, the incidence and prevalence of AD are increasing year by year, which has brought heavy mental and economic burdens to patients, families and society. According to reports, in European and American countries, 4%-12% of the elderly over the age of 60 develop dementia, and more than half of them are AD. Recent survey results show that the incidence of dementia in my country is close to that of European and American countries. There are more than 5 million elderly patients with dementia, of which AD accounts for 2 / 3. [0003] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/675A61P25/28A61P39/06A61K31/122A61K31/4738
Inventor 钟春玖顾建新
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com